Page last updated: 2024-12-11

silatrane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

silatrane: RN given refers to unspecified silatrane [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6328633
CHEMBL ID1992781
SCHEMBL ID311425
MeSH IDM0064815

Synonyms (13)

Synonym
silatrane
4,6,11-trioxa-1-aza-5-silabicyclo[3.3.3]undecane
2,8,9-trioxa-5-aza-1-silabicyclo[3.3.3]undecane
NCI60_008396
2,8,9-trioxa-5-aza-1-silabicyclo(3.3.3)undecane
einecs 206-004-0
283-60-3
AKOS006272947
unii-gr8p7y2mzw
gr8p7y2mzw ,
SCHEMBL311425
DTXSID0058352
CHEMBL1992781

Research Excerpts

Treatment

ExcerptReferenceRelevance
"The silatrane-treated animals were either free of palpable tumors or developed tumors much more slowly in comparison with the control animals without silatranes."( Antitumor effect of novel silatranes on renal cell carcinoma in mice.
Grna, A; Hogan, J; Koo, PH,
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (36.36)18.7374
1990's2 (9.09)18.2507
2000's4 (18.18)29.6817
2010's6 (27.27)24.3611
2020's2 (9.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.90

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.90 (24.57)
Research Supply Index3.53 (2.92)
Research Growth Index4.76 (4.65)
Search Engine Demand Index39.34 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.90)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.03%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other32 (96.97%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]